CRISPR Therapeutics AG
For the period ended Dec 31, 2025. Filed Feb 12, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Feb 12, 2026
CRSP$45.15-9.8%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 8. Consolidated Statements of Cash Flows
Consolidated Statements of Cash Flows
(In thousands)
| Years Ended December 31, | |||
|---|---|---|---|
| 2025 | 2024 | 2023 | |
| Operating activities | |||
| Net loss | $(581,599) | $(366,252) | $(153,610) |
| Reconciliation of net loss to net cash used in operating activities: | |||
| Depreciation and amortization | 19,479 | 19,259 | 19,837 |
| Stock-based compensation expense | 72,499 | 86,567 | 81,028 |
| Other non-cash items, net | (23,528) | (38,618) | (16,545) |
| Acquired in-process research and development | 96,253 | — | 2,500 |
| Changes in: | |||
| Accounts receivable | 25,000 | 175,000 | (200,000) |
| Prepaid expenses and other assets | 3,337 | 5,285 | 23,219 |
| Accounts payable and accrued expenses | 44,894 | (27,283) | (20,247) |
| Deferred revenue | (397) | (1,949) | 5,794 |
| Operating lease assets and liabilities | (5,210) | (4,407) | (2,461) |
| Other liabilities, net | 4,258 | 9,624 | 110 |
| Net cash used in operating activities | (345,014) | (142,774) | (260,375) |
| Investing activities | |||
| Purchase of property, plant and equipment | (914) | (1,901) | (9,470) |
| Purchase of in-process research and development | (25,000) | — | (2,500) |
| Investment in equity securities | (9,700) | (23,183) | — |
| Sale of equity securities | 702 | — | — |
| Purchases of marketable debt securities | (1,008,170) | (1,463,196) | (1,065,911) |
| Maturities of marketable debt securities | 1,011,277 | 1,207,799 | 1,452,528 |
| Net cash used in (provided by) investing activities | (31,805) | (280,481) | 374,647 |
| Financing activities | |||
| Proceeds from issuance of common shares, net of issuance costs | 398,090 | 300,695 | 32,721 |
| Proceeds from exercise of options and ESPP contributions, net of issuance costs | 27,936 | 31,289 | 29,943 |
| Net cash provided by financing activities | 426,026 | 331,984 | 62,664 |
| Effect of exchange rate changes on cash | 95 | (21) | 73 |
| Increase (decrease) in cash | 49,302 | (91,292) | 177,009 |
| Cash, cash equivalents and restricted cash, beginning of period | 309,776 | 401,068 | 224,060 |
| Cash, cash equivalents and restricted cash, end of period | $359,078 | $309,776 | $401,068 |
| Supplemental disclosure of non-cash investing and financing activities | |||
| Property and equipment purchases in accounts payable and accrued expenses | $394 | $154 | $725 |
| Equity issuance costs in accounts payable and accrued expenses | $4,799 | $3,371 | $417 |
| Acquired in-process research and development expense related to issuance of common shares | $71,253 | $— | $— |
| Reconciliation to amounts within the consolidated balance sheets | As of December 31, | ||
|---|---|---|---|
| 2025 | 2024 | 2023 | |
| Cash and cash equivalents | 347,559 | 298,257 | 389,477 |
| Restricted cash included in prepaid expenses and other current assets | 3,890 | — | — |
| Restricted cash | 7,629 | 11,519 | 11,591 |
| Total | $359,078 | $309,776 | $401,068 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.